{"id":354785,"date":"2026-11-19T13:09:48","date_gmt":"2026-11-19T07:39:48","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=354785"},"modified":"2026-11-19T13:09:48","modified_gmt":"2026-11-19T07:39:48","slug":"pharma-stocks-to-watch-in-2027","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/pharma-stocks-to-watch-in-2027\/","title":{"rendered":"Top 3 Pharma Stocks to Watch in 2027: Divi&#8217;s Labs, Mankind Pharma and Aurobindo Pharma"},"content":{"rendered":"<p style=\"border-left:4px solid #1F4E79;background:#EBF3FB;padding:10px 16px;font-style:italic;\"><em>Divi&#8217;s Labs Rs 11,049.00, Q2 PAT +63.6%. Mankind Pharma Rs 2,625.00, Q2 PAT +37.7%. Aurobindo Pharma Rs 1,796.30, Q2 PAT +32.5%. Prices as of 18 Nov 2026.<\/em><\/p>\n<div style=\"background:#F0F9FF;border-left:4px solid #2E7D32;border-radius:6px;padding:14px 18px;margin:18px 0;\">\n<p style=\"margin:0;color:#1F4E79;font-size:14px;\"><strong>Quick Answer<\/strong><\/p>\n<p style=\"margin:8px 0 0;\">The pharma stocks to watch in 2027 are Divi&#8217;s Laboratories, Mankind Pharma and Aurobindo Pharma, based on their latest results, returns and balance sheets. Divi&#8217;s Labs leads on both recent profit growth and return on equity, while Aurobindo Pharma is the most attractively valued. The best figures in the group are 63.6% quarterly profit growth, a PE of 25.99 and a return on equity of 18.69%. Each stock has its own risks, so investors should match the choice to their holding period and risk appetite.<\/p>\n<\/p><\/div>\n<p>The <strong>pharma stocks to watch in 2027<\/strong> are best picked on reported numbers. US generic launches, contract manufacturing for global drug makers and steady domestic demand are driving Indian pharma, and the three companies on this list grew September 2026 quarter profit by more than 32%.<\/p>\n<p>This list covers Divi&#8217;s Laboratories, Mankind Pharma and Aurobindo Pharma. Each company is assessed on quarterly and annual profit growth, return on equity, debt, valuation and where its share price sits in its 52-week range. Prices are as of the 18 November 2026 close.<\/p>\n<p style=\"margin-top:24px;\"><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&#038;utm_medium=pharma-stocks-to-watch-in-2027\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/pharma-stocks-to-watch-in-2027\/#Top_3_Pharma_Stocks_to_Watch_in_2027_at_a_Glance\" title=\"Top 3 Pharma Stocks to Watch in 2027 at a Glance\">Top 3 Pharma Stocks to Watch in 2027 at a Glance<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/pharma-stocks-to-watch-in-2027\/#Why_Are_These_the_Pharma_Stocks_to_Watch_in_2027\" title=\"Why Are These the Pharma Stocks to Watch in 2027?\">Why Are These the Pharma Stocks to Watch in 2027?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/pharma-stocks-to-watch-in-2027\/#What_Could_Drive_Pharma_Stocks_in_2027\" title=\"What Could Drive Pharma Stocks in 2027?\">What Could Drive Pharma Stocks in 2027?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/pharma-stocks-to-watch-in-2027\/#1_Divis_Laboratories_Contract_Manufacturing_Leader_with_Debt-Free_Balance_Sheet\" title=\"1. Divi&#8217;s Laboratories: Contract Manufacturing Leader with Debt-Free Balance Sheet\">1. Divi&#8217;s Laboratories: Contract Manufacturing Leader with Debt-Free Balance Sheet<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/pharma-stocks-to-watch-in-2027\/#Divis_Labs_Financial_Performance\" title=\"Divi&#8217;s Labs Financial Performance\">Divi&#8217;s Labs Financial Performance<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/pharma-stocks-to-watch-in-2027\/#What_to_Watch_in_Divis_Labs_for_2027\" title=\"What to Watch in Divi&#8217;s Labs for 2027\">What to Watch in Divi&#8217;s Labs for 2027<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/pharma-stocks-to-watch-in-2027\/#2_Mankind_Pharma_Domestic_Branded_Medicines_Leader\" title=\"2. Mankind Pharma: Domestic Branded Medicines Leader\">2. Mankind Pharma: Domestic Branded Medicines Leader<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/pharma-stocks-to-watch-in-2027\/#Mankind_Pharma_Financial_Performance\" title=\"Mankind Pharma Financial Performance\">Mankind Pharma Financial Performance<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/pharma-stocks-to-watch-in-2027\/#What_to_Watch_in_Mankind_Pharma_for_2027\" title=\"What to Watch in Mankind Pharma for 2027\">What to Watch in Mankind Pharma for 2027<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/pharma-stocks-to-watch-in-2027\/#3_Aurobindo_Pharma_US_Generics_Leader_at_the_Lowest_PE\" title=\"3. Aurobindo Pharma: US Generics Leader at the Lowest PE\">3. Aurobindo Pharma: US Generics Leader at the Lowest PE<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/pharma-stocks-to-watch-in-2027\/#Aurobindo_Pharma_Financial_Performance\" title=\"Aurobindo Pharma Financial Performance\">Aurobindo Pharma Financial Performance<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/pharma-stocks-to-watch-in-2027\/#What_to_Watch_in_Aurobindo_Pharma_for_2027\" title=\"What to Watch in Aurobindo Pharma for 2027\">What to Watch in Aurobindo Pharma for 2027<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/pharma-stocks-to-watch-in-2027\/#How_Do_Divis_Labs_Mankind_Pharma_and_Aurobindo_Pharma_Compare\" title=\"How Do Divi&#8217;s Labs, Mankind Pharma and Aurobindo Pharma Compare?\">How Do Divi&#8217;s Labs, Mankind Pharma and Aurobindo Pharma Compare?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/pharma-stocks-to-watch-in-2027\/#Key_Risks_for_Pharma_Stocks_in_2027\" title=\"Key Risks for Pharma Stocks in 2027\">Key Risks for Pharma Stocks in 2027<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/pharma-stocks-to-watch-in-2027\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/pharma-stocks-to-watch-in-2027\/#Frequently_Asked_Questions_on_Pharma_Stocks_to_Watch_in_2027\" title=\"Frequently Asked Questions on Pharma Stocks to Watch in 2027\">Frequently Asked Questions on Pharma Stocks to Watch in 2027<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/pharma-stocks-to-watch-in-2027\/#Which_are_the_best_pharma_stocks_to_watch_in_2027\" title=\"Which are the best pharma stocks to watch in 2027?\">Which are the best pharma stocks to watch in 2027?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/pharma-stocks-to-watch-in-2027\/#Which_pharma_stock_has_grown_profit_the_fastest\" title=\"Which pharma stock has grown profit the fastest?\">Which pharma stock has grown profit the fastest?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/pharma-stocks-to-watch-in-2027\/#Which_of_these_pharma_stocks_is_the_most_attractively_valued\" title=\"Which of these pharma stocks is the most attractively valued?\">Which of these pharma stocks is the most attractively valued?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/univest.in\/blogs-2\/pharma-stocks-to-watch-in-2027\/#Which_pharma_stock_has_the_lowest_valuation\" title=\"Which pharma stock has the lowest valuation?\">Which pharma stock has the lowest valuation?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/univest.in\/blogs-2\/pharma-stocks-to-watch-in-2027\/#What_are_the_key_risks_for_pharma_stocks_in_2027\" title=\"What are the key risks for pharma stocks in 2027?\">What are the key risks for pharma stocks in 2027?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-22\" href=\"https:\/\/univest.in\/blogs-2\/pharma-stocks-to-watch-in-2027\/#Should_I_invest_in_pharma_stocks_for_the_long_term\" title=\"Should I invest in pharma stocks for the long term?\">Should I invest in pharma stocks for the long term?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Top_3_Pharma_Stocks_to_Watch_in_2027_at_a_Glance\"><\/span><strong>Top 3 Pharma Stocks to Watch in 2027 at a Glance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Divi&#8217;s Labs, Mankind Pharma and Aurobindo Pharma have a combined market capitalisation of about Rs 5.07 lakh crore. The table below compares these pharma stocks to watch in 2027 on the metrics that matter most for long-term investors.<\/p>\n<table border=\"1\" cellpadding=\"6\" cellspacing=\"0\">\n<thead>\n<tr>\n<th>Metric<\/th>\n<th>Divi&#8217;s Labs<\/th>\n<th>Mankind Pharma<\/th>\n<th>Aurobindo Pharma<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Company<\/td>\n<td><a href=\"https:\/\/univest.in\/stocks\/divislab\/divi's-laboratories-ltd-share-price-today\">Divi&#8217;s Laboratories<\/a><\/td>\n<td><a href=\"https:\/\/univest.in\/stocks\/mankind\/mankind-pharma-ltd-share-price-today\">Mankind Pharma<\/a><\/td>\n<td><a href=\"https:\/\/univest.in\/stocks\/auropharma\/aurobindo-pharma-ltd-share-price-today\">Aurobindo Pharma<\/a><\/td>\n<\/tr>\n<tr>\n<td>NSE Symbol<\/td>\n<td>DIVISLAB<\/td>\n<td>MANKIND<\/td>\n<td>AUROPHARMA<\/td>\n<\/tr>\n<tr>\n<td>Share Price (Rs)<\/td>\n<td>11,049.00<\/td>\n<td>2,625.00<\/td>\n<td>1,796.30<\/td>\n<\/tr>\n<tr>\n<td>52-Week Closing High (Rs)<\/td>\n<td>11,565.50<\/td>\n<td>2,668.30<\/td>\n<td>1,855.30<\/td>\n<\/tr>\n<tr>\n<td>52-Week Closing Low (Rs)<\/td>\n<td>5,821.00<\/td>\n<td>1,927.40<\/td>\n<td>1,121.70<\/td>\n<\/tr>\n<tr>\n<td>Market Cap (Rs Cr)<\/td>\n<td>2,93,874<\/td>\n<td>1,09,040<\/td>\n<td>1,03,626<\/td>\n<\/tr>\n<tr>\n<td>PE Ratio<\/td>\n<td>87.39<\/td>\n<td>48.17<\/td>\n<td>25.99<\/td>\n<\/tr>\n<tr>\n<td>ROE<\/td>\n<td>18.69%<\/td>\n<td>12.76%<\/td>\n<td>10.13%<\/td>\n<\/tr>\n<tr>\n<td>Debt to Equity<\/td>\n<td>0.00<\/td>\n<td>0.31<\/td>\n<td>0.22<\/td>\n<\/tr>\n<tr>\n<td>Dividend Yield<\/td>\n<td>0.27%<\/td>\n<td>0.04%<\/td>\n<td>0.22%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>On valuation, the stocks trade at the following PE ratios: Divi&#8217;s Labs at 87.39 against an industry PE of 40.12; Mankind Pharma at 48.17 against an industry PE of 40.12; Aurobindo Pharma at 25.99 against an industry PE of 40.12. Aurobindo Pharma trades below the industry multiple, while Divi&#8217;s Labs and Mankind Pharma carry a premium that the market usually pays for faster growth or stronger returns.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Are_These_the_Pharma_Stocks_to_Watch_in_2027\"><\/span><strong>Why Are These the Pharma Stocks to Watch in 2027?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>These three made the list of pharma stocks to watch in 2027 because of earnings delivery and balance sheet quality. Indian pharma companies earn money in three main ways: selling branded medicines in India, exporting generic drugs to the US and Europe, and manufacturing ingredients or drugs for global pharma companies under contract. The three stocks on this list each lead one of these models.<\/p>\n<p>In the September 2026 quarter, net profit grew 63.6% at Divi&#8217;s Labs, 37.7% at Mankind Pharma and 32.5% at Aurobindo Pharma. Return on equity ranges from 10.13% to 18.69%, which shows how efficiently each company uses shareholder capital. Divi&#8217;s Labs runs with little or no debt.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"What_Could_Drive_Pharma_Stocks_in_2027\"><\/span><strong>What Could Drive Pharma Stocks in 2027?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Pharma stocks in 2027 will be driven by new US generic approvals, pricing pressure in the US generics market, growth in chronic therapies in India, and contract manufacturing orders as global drug makers diversify their supply chains.<\/p>\n<p>US FDA inspection outcomes are a key risk to track, since a warning letter can delay approvals from a plant. Divi&#8217;s Laboratories and Aurobindo Pharma are constituents of the <a href=\"https:\/\/univest.in\/indices\/nifty-pharma\/nifty-pharma-share-price-today\">Nifty Pharma<\/a>, so their results move the sector index.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"1_Divis_Laboratories_Contract_Manufacturing_Leader_with_Debt-Free_Balance_Sheet\"><\/span><strong>1. Divi&#8217;s Laboratories: Contract Manufacturing Leader with Debt-Free Balance Sheet<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Divi&#8217;s Laboratories makes active pharmaceutical ingredients and custom-synthesised molecules for global pharma companies, and it is one of the world&#8217;s largest makers of several generic APIs.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Divis_Labs_Financial_Performance\"><\/span><strong>Divi&#8217;s Labs Financial Performance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<table border=\"1\" cellpadding=\"6\" cellspacing=\"0\">\n<thead>\n<tr>\n<th>Metric<\/th>\n<th>Latest<\/th>\n<th>Year Earlier<\/th>\n<th>Change<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Revenue (Rs Cr)<\/td>\n<td>3,770<\/td>\n<td>2,860<\/td>\n<td>+31.8%<\/td>\n<\/tr>\n<tr>\n<td>Net Profit (Rs Cr)<\/td>\n<td>1,127<\/td>\n<td>689<\/td>\n<td>+63.6%<\/td>\n<\/tr>\n<tr>\n<td>Revenue FY26 vs FY25 (Rs Cr)<\/td>\n<td>11,067<\/td>\n<td>9,712<\/td>\n<td>+14.0%<\/td>\n<\/tr>\n<tr>\n<td>Net Profit FY26 vs FY25 (Rs Cr)<\/td>\n<td>2,568<\/td>\n<td>2,191<\/td>\n<td>+17.2%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>For FY26, revenue came in at Rs 11,067 crore (+14.0%), and net profit rose 17.2% to Rs 2,568 crore.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_to_Watch_in_Divis_Labs_for_2027\"><\/span><strong>What to Watch in Divi&#8217;s Labs for 2027<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Divi&#8217;s Labs grew September 2026 quarter net profit 63.6% to Rs 1,127 crore on 31.8% higher revenue, the fastest in this group, and it has the highest ROE at 18.69% with no debt. Its PE of 87.39 is far above the industry PE of 40.12, so investors should be careful about valuation and track new custom synthesis contracts. The stock closed at Rs 11,049.00 on 18 November 2026, about 4.5% below its 52-week closing high of Rs 11,565.50 and 89.8% above its 52-week closing low of Rs 5,821.00.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"2_Mankind_Pharma_Domestic_Branded_Medicines_Leader\"><\/span><strong>2. Mankind Pharma: Domestic Branded Medicines Leader<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Mankind Pharma is one of India&#8217;s largest domestic pharma companies by sales volume, known for brands such as Manforce, Prega News and Gas-O-Fast, with a strong presence in smaller towns.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Mankind_Pharma_Financial_Performance\"><\/span><strong>Mankind Pharma Financial Performance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<table border=\"1\" cellpadding=\"6\" cellspacing=\"0\">\n<thead>\n<tr>\n<th>Metric<\/th>\n<th>Latest<\/th>\n<th>Year Earlier<\/th>\n<th>Change<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Revenue (Rs Cr)<\/td>\n<td>4,432.71<\/td>\n<td>3,789.03<\/td>\n<td>+17.0%<\/td>\n<\/tr>\n<tr>\n<td>Net Profit (Rs Cr)<\/td>\n<td>716.12<\/td>\n<td>520.18<\/td>\n<td>+37.7%<\/td>\n<\/tr>\n<tr>\n<td>Revenue FY26 vs FY25 (Rs Cr)<\/td>\n<td>14,636.43<\/td>\n<td>12,744.23<\/td>\n<td>+14.8%<\/td>\n<\/tr>\n<tr>\n<td>Net Profit FY26 vs FY25 (Rs Cr)<\/td>\n<td>1,938.10<\/td>\n<td>2,006.59<\/td>\n<td>Lower YoY<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>For FY26, revenue came in at Rs 14,636.43 crore (+14.8%), and net profit stood at Rs 1,938.10 crore. Net profit has compounded at about 7.5% a year from FY22 to FY26.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_to_Watch_in_Mankind_Pharma_for_2027\"><\/span><strong>What to Watch in Mankind Pharma for 2027<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Mankind Pharma grew September 2026 quarter net profit 37.7% to Rs 716.12 crore on 17.0% higher revenue. Investors should track the integration of its Bharat Serums and Vaccines acquisition, which added women&#8217;s health and critical care products. The stock closed at Rs 2,625.00 on 18 November 2026, about 1.6% below its 52-week closing high of Rs 2,668.30 and 36.2% above its 52-week closing low of Rs 1,927.40.<\/p>\n<p style=\"margin-top:24px;\"><a href=\"https:\/\/univest.in\/screeners\"><strong>Compare Pharma Stocks on the Univest Screener<\/strong><\/a><\/p>\n<h2><span class=\"ez-toc-section\" id=\"3_Aurobindo_Pharma_US_Generics_Leader_at_the_Lowest_PE\"><\/span><strong>3. Aurobindo Pharma: US Generics Leader at the Lowest PE<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Aurobindo Pharma is one of the largest Indian exporters of generic medicines to the US and Europe, with a wide portfolio of oral, injectable and biosimilar products.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Aurobindo_Pharma_Financial_Performance\"><\/span><strong>Aurobindo Pharma Financial Performance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<table border=\"1\" cellpadding=\"6\" cellspacing=\"0\">\n<thead>\n<tr>\n<th>Metric<\/th>\n<th>Latest<\/th>\n<th>Year Earlier<\/th>\n<th>Change<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Revenue (Rs Cr)<\/td>\n<td>10,431.51<\/td>\n<td>8,406.29<\/td>\n<td>+24.1%<\/td>\n<\/tr>\n<tr>\n<td>Net Profit (Rs Cr)<\/td>\n<td>1,123.84<\/td>\n<td>848.13<\/td>\n<td>+32.5%<\/td>\n<\/tr>\n<tr>\n<td>Revenue FY26 vs FY25 (Rs Cr)<\/td>\n<td>34,145.17<\/td>\n<td>32,345.58<\/td>\n<td>+5.6%<\/td>\n<\/tr>\n<tr>\n<td>Net Profit FY26 vs FY25 (Rs Cr)<\/td>\n<td>3,502.97<\/td>\n<td>3,483.57<\/td>\n<td>+0.6%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>For FY26, revenue came in at Rs 34,145.17 crore (+5.6%), and net profit rose 0.6% to Rs 3,502.97 crore. Net profit has compounded at about 7.3% a year from FY22 to FY26.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_to_Watch_in_Aurobindo_Pharma_for_2027\"><\/span><strong>What to Watch in Aurobindo Pharma for 2027<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Aurobindo Pharma grew September 2026 quarter net profit 32.5% to Rs 1,123.84 crore and revenue 24.1% to Rs 10,431.51 crore. It trades at a PE of 25.99, the lowest of the three and below the industry PE of 40.12. Investors should track US FDA inspection outcomes and its biosimilars pipeline. The stock closed at Rs 1,796.30 on 18 November 2026, about 3.2% below its 52-week closing high of Rs 1,855.30 and 60.1% above its 52-week closing low of Rs 1,121.70.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"How_Do_Divis_Labs_Mankind_Pharma_and_Aurobindo_Pharma_Compare\"><\/span><strong>How Do Divi&#8217;s Labs, Mankind Pharma and Aurobindo Pharma Compare?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The table below puts quarterly growth, annual profit, valuation and price position for the three pharma stocks side by side.<\/p>\n<table border=\"1\" cellpadding=\"6\" cellspacing=\"0\">\n<thead>\n<tr>\n<th>Metric<\/th>\n<th>Divi&#8217;s Labs<\/th>\n<th>Mankind Pharma<\/th>\n<th>Aurobindo Pharma<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Q2 Net Profit Growth<\/td>\n<td>+63.6%<\/td>\n<td>+37.7%<\/td>\n<td>+32.5%<\/td>\n<\/tr>\n<tr>\n<td>Latest Annual Net Profit (Rs Cr)<\/td>\n<td>2,568<\/td>\n<td>1,938.10<\/td>\n<td>3,502.97<\/td>\n<\/tr>\n<tr>\n<td>PE vs Industry PE<\/td>\n<td>87.39 vs 40.12<\/td>\n<td>48.17 vs 40.12<\/td>\n<td>25.99 vs 40.12<\/td>\n<\/tr>\n<tr>\n<td>Distance from 52-Week Closing High<\/td>\n<td>4.5% below<\/td>\n<td>1.6% below<\/td>\n<td>3.2% below<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>For investors building a list of pharma stocks to watch in 2027, the right pick depends on priorities. Those who want growth momentum and capital efficiency may track Divi&#8217;s Labs and investors who want valuation comfort may prefer Aurobindo Pharma. Mankind Pharma gives exposure to a different part of the sector.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks_for_Pharma_Stocks_in_2027\"><\/span><strong>Key Risks for Pharma Stocks in 2027<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Even the strongest pharma stocks to watch in 2027 carry risks that investors should weigh before buying.<\/p>\n<p><strong>US pricing pressure:<\/strong> Price erosion in US generics can reduce margins even when volumes grow.<\/p>\n<p><strong>Regulatory action:<\/strong> US FDA warning letters or import alerts can stop shipments from a plant.<\/p>\n<p><strong>Currency moves:<\/strong> A stronger rupee reduces the value of export revenue.<\/p>\n<p><strong>Valuation:<\/strong> Divi&#8217;s Labs and Mankind Pharma trade above the industry PE, so a slowdown in growth can lead to price corrections. Staggered buying helps manage entry risk.<\/p>\n<p style=\"margin-top:24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&#038;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track Divi&#8217;s Labs, Mankind Pharma and Aurobindo Pharma live and get daily stock research.<\/em><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Divi&#8217;s Laboratories, Mankind Pharma and Aurobindo Pharma stand out among pharma stocks to watch in 2027 on growth, returns and balance sheet strength. Before investing, compare each stock&#8217;s PE with its profit growth, check where it trades in its 52-week range, and track the December and March quarter results to confirm the trend into 2027. Building positions gradually suits a sector where earnings can swing with US pricing pressure.<\/p>\n<div style=\"background:#CC0000;border-radius:8px;padding:16px 20px;margin:24px 0;\">\n<p style=\"color:#FFFFFF;font-size:13px;line-height:1.7;margin:0;\"><strong style=\"color:#FFFFFF;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/p><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions_on_Pharma_Stocks_to_Watch_in_2027\"><\/span><strong>Frequently Asked Questions on Pharma Stocks to Watch in 2027<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Which_are_the_best_pharma_stocks_to_watch_in_2027\"><\/span><strong>Which are the best pharma stocks to watch in 2027?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Divi&#8217;s Laboratories, Mankind Pharma and Aurobindo Pharma are three of the strongest pharma stocks to watch in 2027 based on reported numbers. Divi&#8217;s Labs leads on both recent profit growth and return on equity, while Aurobindo Pharma is the most attractively valued. The strongest figures in the group are 63.6% quarterly profit growth, a 18.69% return on equity and a PE of 25.99. Each company covers a different part of the pharma space, so the best choice depends on whether an investor prefers growth, value or capital efficiency. Investors should match the pick to their own risk profile and holding period.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Which_pharma_stock_has_grown_profit_the_fastest\"><\/span><strong>Which pharma stock has grown profit the fastest?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Divi&#8217;s Laboratories has grown profit the fastest among these three, with September 2026 quarter net profit up 63.6% year on year to Rs 1,127 crore. Mankind Pharma follows with 37.7% growth. Divi&#8217;s Labs&#8217;s latest annual net profit stood at Rs 2,568 crore for FY26. Quarterly growth can swing with seasonality and one-time items, so investors should compare several quarters before drawing conclusions. Margins and demand trends over the next two quarters will show whether this pace can continue into 2027.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Which_of_these_pharma_stocks_is_the_most_attractively_valued\"><\/span><strong>Which of these pharma stocks is the most attractively valued?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Aurobindo Pharma is the most attractively valued of the three, with a PE of 25.99 against an industry PE of 40.12. Mankind Pharma trades at 48.17 and Divi&#8217;s Labs at 87.39. A lower PE can signal value, but it can also reflect slower growth or higher risk, so it should be read with profit growth and return on equity. Investors should also check where each stock trades within its 52-week range before deciding on an entry point.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Which_pharma_stock_has_the_lowest_valuation\"><\/span><strong>Which pharma stock has the lowest valuation?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Aurobindo Pharma has the lowest valuation of the three with a PE of 25.99, against an industry PE of 40.12. Mankind Pharma trades at 48.17 and Divi&#8217;s Laboratories at 87.39. Aurobindo&#8217;s lower PE reflects its exposure to the price-competitive US generics market, while Divi&#8217;s commands a premium for its contract manufacturing model and debt-free balance sheet. Investors should compare profit growth and return on equity along with the PE before deciding, since Divi&#8217;s also grew quarterly profit the fastest at 63.6%.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_are_the_key_risks_for_pharma_stocks_in_2027\"><\/span><strong>What are the key risks for pharma stocks in 2027?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The main risks for pharma stocks in 2027 are US pricing pressure, regulatory action and currency moves. Price erosion in US generics can reduce margins even when volumes grow. Valuation is another risk, since Divi&#8217;s Labs and Mankind Pharma trade above the industry PE. US FDA warning letters or import alerts can stop shipments from a plant. A stronger rupee reduces the value of export revenue. Investors should review quarterly results, avoid putting too much money into a single stock, and size positions according to their risk tolerance.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Should_I_invest_in_pharma_stocks_for_the_long_term\"><\/span><strong>Should I invest in pharma stocks for the long term?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Pharma stocks can suit long-term investors who understand the sector&#8217;s cycles and are comfortable with price swings. Divi&#8217;s Labs, Mankind Pharma and Aurobindo Pharma have shown profit growth and healthy returns on equity, which are good signs for long-term holders. Divi&#8217;s Labs earns a 18.69% return on equity, which shows how efficiently it uses shareholder money. Building positions gradually, for example through staggered purchases, usually works better than buying a full position at once. Before investing, check your asset allocation and consider speaking with a SEBI-registered investment adviser.<\/p>\n<div class=\"faq-schema\"><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"Which are the best pharma stocks to watch in 2027?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Divi's Laboratories, Mankind Pharma and Aurobindo Pharma are three of the strongest pharma stocks to watch in 2027 based on reported numbers. Divi's Labs leads on both recent profit growth and return on equity, while Aurobindo Pharma is the most attractively valued. The strongest figures in the group are 63.6% quarterly profit growth, a 18.69% return on equity and a PE of 25.99. Each company covers a different part of the pharma space, so the best choice depends on whether an investor prefers growth, value or capital efficiency. Investors should match the pick to their own risk profile and holding period.\"}},{\"@type\":\"Question\",\"name\":\"Which pharma stock has grown profit the fastest?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Divi's Laboratories has grown profit the fastest among these three, with September 2026 quarter net profit up 63.6% year on year to Rs 1,127 crore. Mankind Pharma follows with 37.7% growth. Divi's Labs's latest annual net profit stood at Rs 2,568 crore for FY26. Quarterly growth can swing with seasonality and one-time items, so investors should compare several quarters before drawing conclusions. Margins and demand trends over the next two quarters will show whether this pace can continue into 2027.\"}},{\"@type\":\"Question\",\"name\":\"Which of these pharma stocks is the most attractively valued?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Aurobindo Pharma is the most attractively valued of the three, with a PE of 25.99 against an industry PE of 40.12. Mankind Pharma trades at 48.17 and Divi's Labs at 87.39. A lower PE can signal value, but it can also reflect slower growth or higher risk, so it should be read with profit growth and return on equity. Investors should also check where each stock trades within its 52-week range before deciding on an entry point.\"}},{\"@type\":\"Question\",\"name\":\"Which pharma stock has the lowest valuation?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Aurobindo Pharma has the lowest valuation of the three with a PE of 25.99, against an industry PE of 40.12. Mankind Pharma trades at 48.17 and Divi's Laboratories at 87.39. Aurobindo's lower PE reflects its exposure to the price-competitive US generics market, while Divi's commands a premium for its contract manufacturing model and debt-free balance sheet. Investors should compare profit growth and return on equity along with the PE before deciding, since Divi's also grew quarterly profit the fastest at 63.6%.\"}},{\"@type\":\"Question\",\"name\":\"What are the key risks for pharma stocks in 2027?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The main risks for pharma stocks in 2027 are US pricing pressure, regulatory action and currency moves. Price erosion in US generics can reduce margins even when volumes grow. Valuation is another risk, since Divi's Labs and Mankind Pharma trade above the industry PE. US FDA warning letters or import alerts can stop shipments from a plant. A stronger rupee reduces the value of export revenue. Investors should review quarterly results, avoid putting too much money into a single stock, and size positions according to their risk tolerance.\"}},{\"@type\":\"Question\",\"name\":\"Should I invest in pharma stocks for the long term?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Pharma stocks can suit long-term investors who understand the sector's cycles and are comfortable with price swings. Divi's Labs, Mankind Pharma and Aurobindo Pharma have shown profit growth and healthy returns on equity, which are good signs for long-term holders. Divi's Labs earns a 18.69% return on equity, which shows how efficiently it uses shareholder money. Building positions gradually, for example through staggered purchases, usually works better than buying a full position at once. Before investing, check your asset allocation and consider speaking with a SEBI-registered investment adviser.\"}}]}<\/script><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Divi&#8217;s Labs, Mankind Pharma and Aurobindo Pharma are three pharma stocks to watch in 2027, compared on September 2026 quarter profit growth, ROE, debt, valuation and 52-week range.<\/p>\n","protected":false},"author":35,"featured_media":354784,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[24],"tags":[10618,457,805,1007,8497],"class_list":["post-354785","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-market","tag-aurobindo-pharma","tag-divis-laboratories","tag-mankind-pharma","tag-pharma-stocks","tag-pharmaceutical-stocks"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["354784"],"rank_math_title":["Pharma Stocks to Watch in 2027: Divi's, Mankind, Aurobindo"],"rank_math_description":["Pharma stocks to watch in 2027: Divi's Labs, Mankind Pharma and Aurobindo Pharma compared on September 2026 quarter profit, ROE, debt, PE and 52-week range."],"rank_math_focus_keyword":["pharma stocks to watch in 2027"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/11\/top-3-pharma-stocks-to-watch-in-2027-divi-s-labs-mankind-pharma-and-aurobindo.webp","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/354785","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/35"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=354785"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/354785\/revisions"}],"predecessor-version":[{"id":354786,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/354785\/revisions\/354786"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/354784"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=354785"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=354785"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=354785"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}